Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Portfolio Pulse from Happy Mohamed
Cantex Pharmaceuticals has obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent, or alleviate cancer-treatment related cognitive decline. Pre-clinical studies at Georgetown's Lombardi Comprehensive Cancer Center suggest azeliragon may help treat cognitive symptoms associated with cancer chemotherapy and reduce the risk of metastatic breast cancer.
June 01, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
vTv Therapeutics, the company that discovered azeliragon, may benefit from Cantex Pharmaceuticals' exclusive worldwide license for the drug's potential use in treating cancer-related cognitive decline.
vTv Therapeutics discovered azeliragon and licensed it to Cantex Pharmaceuticals. Cantex obtaining an exclusive worldwide license for the drug's potential use in treating cancer-related cognitive decline may lead to increased interest in vTv Therapeutics' stock, as it highlights the potential of their discovery.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50